Patients with Prolonged Positivity of SARS-CoV-2 RNA Benefit from Convalescent Plasma Therapy: A Retrospective Study
- PDF / 481,657 Bytes
- 8 Pages / 595.276 x 790.866 pts Page_size
- 90 Downloads / 158 Views
www.virosin.org www.springer.com/12250
(0123456789().,-volV)(0123456789().,-volV)
RESEARCH ARTICLE
Patients with Prolonged Positivity of SARS-CoV-2 RNA Benefit from Convalescent Plasma Therapy: A Retrospective Study Yongran Wu1 • Ke Hong2 • Lianguo Ruan2 • Xiaobo Yang1 • Jiancheng Zhang1 • Jiqian Xu1 • Shangwen Pan1 Lehao Ren1 • Lu Chen2 • Chaolin Huang2 • You Shang1
•
Received: 9 July 2020 / Accepted: 3 August 2020 Ó Wuhan Institute of Virology, CAS 2020
Abstract Convalescent plasma therapy has been implemented in a few cases of severe coronavirus disease 2019. No report about convalescent plasma therapy in treating patients with prolonged positivity of SARS-CoV-2 RNA has been published. In this study, we conducted a retrospective observational study in 27 patients with prolonged positivity of SARS-CoV-2 RNA, the clinical benefit of convalescent plasma therapy were analyzed. qRT-PCR test of SARS-CoV-2 RNA turned negative (B 7 days) in a part of patients (early negative group, n = 15) after therapy, others (late negative group, n = 12) turned negative in more than 7 days. Pulmonary imaging improvement was confirmed in 7 patients in early negative group and 8 in late negative group after CP therapy. Viral load decreased in early negative group compared with late negative group at day 3, 5, 7 after implementing convalescent plasma therapy. Patients in early negative group had a shorter median length of hospital stay. In conclusion, convalescent plasma therapy might help eliminate virus and shorten length of hospital stay in patients with prolonged positivity of SARS-CoV-2 RNA. Keywords Coronavirus disease 2019 (COVID-19) SARS-CoV-2 Prolonged positivity Convalescent plasma therapy
Introduction The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in late 2019 (Zhu et al. 2020), has been rapidly spreading and causing a worldwide pandemic (Kirby 2020; Saglietto et al. 2020). The pneumonia induced by SARS-CoV-2 is known as coronavirus disease 2019 (COVID-19) (Ivers and Walton 2020). To date, the virus has infected millions of people all over the world.
Yongran Wu, Ke Hong and Lianguo Ruan contributed equally to this work. & You Shang [email protected] & Chaolin Huang [email protected] 1
Department of Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China
2
Research Center for Translational Medicine, Jinyintan Hospital, Wuhan 430022, China
Recently, many studies about long-term viral duration in COVID-19 patients have been published (Liu et al. 2020; Wan et al. 2020; Zhou et al. 2020; Shi et al. 2020; Yang JR et al. 2020; Li et al. 2020). The longest duration observed was 83 days in one patient’s upper respiratory tract samples (Li et al. 2020). Although the association between viral duration and disease severity or older age was inconsistent in different studies, some studies reported longer viral duration correlated with severe disease or older age in COVID-19 patients (Yan et al. 2020; Zhang YC et al.
Data Loading...
